



# ADVISORY

No. 205

February 13, 2020

## Brand Adderall XR® Capsules Removal from DAW 6 Drug Program

**The Office of Pharmacy Services (OPS), formerly known as the Maryland Medicaid Pharmacy Program, wants to alert you that effective Wednesday, March 11, 2020 brand Adderall XR® capsules will no longer be preferred over its generic equivalent (amphetamine salt combo ER capsule).**

Claims for amphetamine salt combo ER capsules will be handled in the same manner as claims for other multisource medications. Claims for brand Adderall XR® capsules will adjudicate only if there is a prior authorization based on an approved Maryland Department of Health (MDH) Medwatch form, which can be found at:

<https://mmcp.health.maryland.gov/pap/docs/Maryland%20Medwatch%20Form.pdf>

Please refer to our website for the complete PDL:

<https://mmcp.health.maryland.gov/pap/pages/Preferred-Drug-List.aspx>

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Maryland Department of Health (**MDH**) **Office of Pharmacy Services (OPS)** has developed the **Maryland Medicaid Pharmacy Program Advisory**.

To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations.

It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via MDH, please contact the OPS representative at 410-767-1455.